



Supplementary Material

Supplementary Table 1. List of antibodies used in flow cytometry. **A.** U937-myeloid cells and **B.** PBMC CD11b isolated myeloid cells.


Antigen	Conjugate	Vendor	Catalog Number	A	B
CD14	APC	Thermo Fisher Scientific	17-0149-42	√	
	Pacific Blue	BioLegend	367122		√
CD68	BV 421	BioLegend	301807	√	
	AF647		333819		√
HLA-DR	PerCP Cy5.5	Thermo Fisher Scientific	45-9956-42	√	
	Brilliant Violet 650	BD Bioscience	564231		√
CD86	PE-Cy7	Thermo Fisher Scientific	25-0869-42	√	
	PE-Cy5		15-0869-42		√
CD163	PE	BioLegend	333606	√	
	APC/Fire™ 750		333634		√
CD206	PE-Cy7	BioLegend	141720		√
CD11c	PerCP Cy5.5	BioLegend	337210		√
CD15	PE	BioLegend	323006		√
Live/Dead marker	Aqua	Thermo Fisher Scientific	L34966	√	√




Supplementary Figure 1. Gating strategy for myeloid cell infiltration using single cell based on forward and side scatters.




Supplementary Figure 2. (A) Heatmap of proteins identified in TD0 secretome. **(B)** Table summary of secretome protein identified. All proteins used in all proteomic analysis were identified with $FDR \leq 0.01$ confidence and was a Master Protein present in at least two of three technical replicates. TD0: Treatment at day 0, TD5: Treatment at day 5, D5: Secretome collected at day 5, D8: Secretome collect at day 8.




Supplementary Figure 3. FunRich quantitative gene ontology analysis in (A-B) immune related biological pathway, (C) transcription factor and (D) site of expression. All proteins used in all proteomic analysis were identified with $FDR \leq 0.01$ confidence and was a Master Protein present in at least two of three technical replicates.



Supplementary Figure 4. Secreted protein abundance of **(A)** IL8, **(B)** LCP1 and **(C)** TAGLN2. **(D)** IL-8 secreted in cell supernatant at day 8 (n =3). All proteins used in all proteomic analysis were identified with FDR ≤ 0.01 confidence and was a Master Protein present in at least two of three technical replicates. Bar chart with mean \pm standard deviation. Statistical analysis one-way ANOVA with Dunnett's multiple comparisons were performed with $**p < 0.01$. emPAI: exponentially modified Protein Abundance Index



Supplementary Figure 5. Infiltration of (A-B) total U937 cells, (C-D) CD14+ monocytes, (E-F) CD163+ macrophages, (G-H) HLA-DR- CD68- MDSCs, and (I-J) CD14-/CD86+ moDCs after treatment at day 0 (TD0, n = 64) and day 5 (TD5, n = 48). Scatter dot plots with median and range are presented. Statistical analysis – one-way ANOVA with Dunnett’s multiple comparisons were performed with * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.



Supplementary Figure 6. Infiltration of (A) total myeloid cells (n=5), (B) mature moDCs (n=5), (C-D) CD86+ M1-like macrophages (n=5), (E-F) CD163+ (n=8) and (G) CD163+ CD206+ (n=3) M2-like macrophages after treatment at day 0 (TD0) and day 5 (TD5). Bar chart with mean \pm standard deviation. Statistical analysis one-way ANOVA Dunnett's multiple comparisons were performed with * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.